Investment Partners LTD. Purchases 53 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Investment Partners LTD. increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.1% during the 4th quarter, Holdings Channel reports. The fund owned 1,095 shares of the medical equipment provider’s stock after buying an additional 53 shares during the quarter. Investment Partners LTD.’s holdings in Intuitive Surgical were worth $369,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ISRG. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in Intuitive Surgical by 0.3% during the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock worth $3,002,000 after acquiring an additional 27 shares in the last quarter. Liberty Capital Management Inc. raised its stake in Intuitive Surgical by 3.8% during the fourth quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 30 shares in the last quarter. Miracle Mile Advisors LLC raised its stake in Intuitive Surgical by 2.3% during the fourth quarter. Miracle Mile Advisors LLC now owns 1,438 shares of the medical equipment provider’s stock worth $485,000 after acquiring an additional 32 shares in the last quarter. Ausdal Financial Partners Inc. raised its stake in Intuitive Surgical by 1.5% during the fourth quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock worth $739,000 after acquiring an additional 33 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its stake in Intuitive Surgical by 10.7% during the fourth quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock worth $115,000 after acquiring an additional 33 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Trading Up 0.6 %

Shares of ISRG traded up $2.21 during trading hours on Friday, reaching $375.33. 927,845 shares of the company’s stock traded hands, compared to its average volume of 1,564,565. The stock has a market cap of $133.13 billion, a PE ratio of 67.75, a price-to-earnings-growth ratio of 4.82 and a beta of 1.36. The firm’s 50 day simple moving average is $386.19 and its 200-day simple moving average is $345.95. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the company posted $1.00 EPS. As a group, analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, CEO Gary S. Guthart sold 24,325 shares of Intuitive Surgical stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $376.06, for a total value of $9,147,659.50. Following the transaction, the chief executive officer now directly owns 9,425 shares of the company’s stock, valued at approximately $3,544,365.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Gary S. Guthart sold 24,325 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $376.06, for a total value of $9,147,659.50. Following the transaction, the chief executive officer now directly owns 9,425 shares in the company, valued at $3,544,365.50. The disclosure for this sale can be found here. Insiders have sold 249,418 shares of company stock valued at $96,300,959 in the last ninety days. Company insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on ISRG. Truist Financial boosted their target price on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Jefferies Financial Group upped their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Barclays increased their price target on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a report on Thursday, January 25th. Robert W. Baird lowered their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Finally, Stifel Nicolaus raised their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.